Millennium Pharmaceuticals has stopped further accrual into its phase II clinical trial investigating the efficacy of bortezomib

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1420, 2004-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alexza Pharmaceuticals has announced that it has completed enrolment in its second phase III trial with loxapine

By  

Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

DOV Pharmaceuticals has announced that dosing has been suspended in its ongoing trial of ocinaplon due to liver enzyme elevations

By  

Reactions Weekly, Vol. 1, Iss. 1069, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

IntraBiotics Pharmaceuticals has discontinued its trial of iseganan for the prevention of ventilator-associated pneumonia

By  

Reactions Weekly, Vol. 1, Iss. 1009, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

By Gomez-Abuin Gonzalo   Winquist Eric   Stadler Walter   Pond Greg   Degendorfer Pamela   Wright John   Moore Malcolm  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 181-185

Springer Publishing Company

Access to resources Recommend Favorite

Millennium Pharmaceuticals

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 11, 2004-11 ,pp. : 1605-1608

Informa Healthcare

Access to resources Recommend Favorite